Study of BMS-275183 in Patients With Pretreated Locally Advanced or Metastatic NSCLC (Non Small Cell Lung Cancer)

Stopped early · Phase 2

Conditions studied: Non-small Cell Lung Cancer

In brief

BMS-275183 given orally twice weekly to patients pretreated for locally advanced or metastatic NSCLC will show anti-tumor activity in any of the 3 separate cohorts of the patients enrolled: * Cohort I: Patients previously treated with one taxane containing regimen. * Cohort II: Patients previously treated with a platinum based but non-taxane containing regimen. * Cohort III: Patients previously treated with both a chemotherapy regimen and one EGFR-TKI (epidermal growth factor receptor-tyrosine kinase inhibitor) compound. Patients in cohorts I and II should have not been treated with a prior EGFR-TKI compound. Prior treatment with a VEGFR (vascular endothelial growth factor receptor) inhibitor compound is allowed for all the patients provided that the VEGFR inhibitor is not also an EGFR inhibitor.

Key facts

Study ID

NCT00359450

Run by

Bristol-Myers Squibb

People needed

186

Starts

2006-07-01

Last updated by the study team

2010-03-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Men and women, age >= 18 years
• Subjects with histologically or cytologically confirmed locally advanced or metastatic NSCLC who failed only one prior chemotherapy regimen.

You may not qualify if…

• Concomitant medication with a cytochrome P450 (CYP) 3A4 inhibitor or inducer

Where it is running

• Local Institution — Burlington, Massachusetts, United States
• Local Institution — St Louis, Missouri, United States
• Local Institution — Morganton, North Carolina, United States
• Local Institution — Cleveland, Ohio, United States
• Local Institution — Charleroi, Belgium
• Local Institution — Leuven, Belgium
• Local Institution — Montreal, Ontario, Canada
• Local Institution — Thunder Bay, Ontario, Canada
• Local Institution — Toronto, Ontario, Canada
• Local Institution — Saint-Jérôme, Quebec, Canada
• Local Institution — Belfort, France
• Local Institution — Besançon, France
• Local Institution — Poitiers, France
• Local Institution — Saint-Herblain, France
• Local Institution — Strasbourg, France
• Local Institution — Tours, France
• Local Institution — Naples, Italy
• Local Institution — Orbassano Torino, Italy
• Local Institution — Perugia, Italy
• Local Institution — Roma, Italy
• Local Institution — Amsterdam, Netherlands
• Local Institution — Maastricht, Netherlands
• Local Institution — Barcelona, Spain
• Local Institution — Madrid, Spain
• Local Institution — Cambridge, Cambridgeshire, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.